Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Denmark / NCT07304193
Enrolling by invitation Observational

Clinical and Genetic Aspects of Fetuses With Sex-chromosome Disorders

NCT07304193 · tracked via the Priya Life Science Denmark tracker
Sponsor
University of Aarhus
Phase
Observational
Started
2024-01-01
Last updated
2026-01-08

Condition(s) studied

Sex Chromosome Disorders

Study summary

To conduct a comprehensive clinical investigation of electively aborted fetuses with sex chromosome disorders and their placentas, in parallel with analyses of epigenetic alterations and changes in gene expression in these fetuses and their placentas, with the aims to:

1. delineate how variations in sex chromosome number affect the epigenetic and genetic mechanisms regulating gene expression in the placenta and in multiple fetal tissues in fetuses with sex chromosome disorders;
2. identify the epigenetic and genetic mechanisms and placental and fetal alterations that underlie the phenotypic manifestations observed in fetuses with sex chromosome disorders.

Eligibility

Sex
ALL
Min age
11 Weeks
Max age
22 Weeks
Healthy volunteers
No
Inclusion criteria cases: * Age ≥18 years * Fetuses with genetically verified sex chromosome disorders * Gestational age between 11+0 and 22+6 at the time of abortion or at delivery due to intrauterine fetal death * Written informed consent Inclusion criteria cases: * Age ≥18 years * No known sex chromosome disorder or other genetic disorder in the fetus * No known fetal malformations * Fetal growth within the normal range * Gestational age between 11+0 and 22+6 at the time of abortion

Primary outcome measure(s)

  • DNA methylation profile — 5 years
    DNA methylation of placenta DNA methylation across fetal tissues
  • Gene expression profile — 5 years
    RNA expression of placenta RNA expression across fetal tissue

Trial sites (1)

FacilityCityRegionStatus
Aarhus University Hospital Aarhus Denmark

More University of Aarhus trials in Denmark

Probiotic Treatment of Orthodontic Patients Recruiting
BPA vs. PEA in CTEPH Recruiting
Precision Treatment of Lumbar Spine Surgery Through Advanced Nerve Root Blockade Recruiting
IMPROVE: Circulating Tumor DNA Analysis to Optimize Treatment for Patients With Colorectal Cancer Active, not recruiting
Danish Access to Support and Help (DASH): Increasing Access to an Evidence-based Intervention for Children With ADHD and Their Parents Enrolling by invitation

Other trials for the same condition

Clinical and Genetic Aspects in Fetuses and Children With Sex Chromosome Disorders Enrolling by invitation
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07304193 on ClinicalTrials.gov ↗ ← All trials in Denmark